Dr. Tsvetnitsky is a seasoned biotech leader with over twenty years of experience in developing vaccines and biotherapeutics. Prior to joining Codagenix, Dr. Tsvetnitsky led process development and manufacturing projects for multiple HIV vaccines at IAVI, a non-profit organization dedicated to vaccine development. As part of the global vaccine development program at PATH, another global non-profit organization, Dr. Tsvetnitsky led efforts to develop better influenza vaccines. Before joining PATH, he led manufacturing development of multiple biotherapeutics at Cangene. Dr. Tsvetnitsky earned his B.Sc./M.Sc. in Chemical Engineering from Moscow Institute of Fine Chemical Technology, and his Ph.D. in Biochemistry from School of Pharmacy, University of London. He completed postdoctoral training at Odense University in Denmark and at London Regional Cancer Center in Canada.